medicaid glp 1 weight loss McKee's proposed FY2027 budget drops GLP-1 drugs for from • Rhode Island Current California Medi-Cal halts GLP-1 obesity

The researchers found that compared with topiramate, GLP-1 RA initiators had a lower risk for emergency department visits (risk ratio [RR], 0.90), hospitalizations (RR, 0.86), nerve blocks (RR, 0.87), and triptan use (RR, 0.87)

If approved, semaglutide 7.2 mg would bring patients and healthcare professionals a new option for greater weight loss potential, further underlining the efficacy that the semaglutide molecule can bring

Its a moment every serious researcher faces

While there is not yet an official timeline, Eli Lilly executives have said they plan to submit orforglipron for federal approval by the end of the year